Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 21, 2023 08:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it...
Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
January 17, 2023 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
January 04, 2023 08:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 15, 2022 08:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it...
Checkpoint Therapeutics Announces Reverse Stock Split
December 05, 2022 16:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it...
Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 08, 2022 16:30 ET
|
Checkpoint Therapeutics, Inc
Successful completion of pre-BLA meetings in July Biologics license application (“BLA”) for both metastatic and locally advanced cutaneous squamous cell carcinoma indications expected to be submitted...
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences
September 22, 2022 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences
September 08, 2022 08:15 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
August 12, 2022 08:00 ET
|
Checkpoint Therapeutics, Inc
Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 Successful completion of pre-BLA meetings in July...
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma
June 16, 2022 07:30 ET
|
Checkpoint Therapeutics, Inc
Objective response rate of 54.8% in patients with locally advanced cSCC, a potential 2nd indication for cosibelimabPreviously met primary endpoint in patients with metastatic cSCC; BLA submission on...